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A human cancer-associated truncation of MBD4 causes dominant
negative impairment of DNA repair in colon cancer cells
SA Bader*,1, M Walker1 and DJ Harrison1
1Department of Pathology, Edinburgh Cancer Research Centre, University of Edinburgh, Crewe Road, Edinburgh EH4 2XR, UK
MBD4 binds to methylated DNA and acts as a thymine DNA glycosylase in base excision repair. Deficiency of MBD4 in mice
enhances mutation at CpG sites and alters apoptosis in response to DNA damage, but does not increase tumorigenesis in mismatch
repair-deficient mice. However, in humans, frameshift mutation of MBD4, rather than deletion, is what occurs in up to 43% of
microsatellite unstable colon cancers. There is no murine equivalent of this mutation. We now show that recombinant truncated
MBD4 (MBD4tru) inhibits glycosylase activities of normal MBD4 or Uracil DNA glycosylase in cell-free assays as a dominant negative
effect. Furthermore, overexpression of MBD4tru in Big Blue (lacI)-transfected, MSI human colorectal carcinoma cells doubled mutation
frequency, indicating that the modest dominant negative effect on DNA repair can occur in living cells in short-term experiments.
Intriguingly, the whole mutation spectrum was increased, not only at CpG sites, suggesting that truncated MBD4 has a more
widespread effect on genomic stability. This demonstration of a dominant negative effect may be of significance in tumour
progression and acquisition of drug resistance.
British Journal of Cancer (2007) 96, 660–666. doi:10.1038/sj.bjc.6603592 www.bjcancer.com
Published online 6 February 2007
& 2007 Cancer Research UK
Keywords: MBD4; colorectal cancer; genomic instability; Big Blue; mutation frequency









































MBD4 is a methyl-CpG-binding DNA glycosylase involved
especially in the repair of mismatches arising from deamination
of methyl-C in mammalian cells. MBD4 has been shown in vitro to
excise mismatched thymine (T) bases from oligo templates
(Hendrich et al, 1999; Petronzelli et al, 2000a, b), and mouse
knockout models have found that in the absence of Mbd4,
mutation frequency (MF) in vivo increases, mainly at methyl-CpG
sites (Millar et al, 2002; Wong et al, 2002). MBD4 can also bind to
MLH1 and Fas-associated death domain (FADD) proteins
(Bellacosa et al, 1999; Screaton et al, 2003), and the small intestine
of Mbd4/ mice shows reduced apoptosis in response to a variety
of DNA-damaging agents (Cortellino et al, 2003; Sansom et al,
2003; Screaton et al, 2003). Absence of Mbd4 in mice also increases
tumorigenicity in the tumour-susceptible APCmin background
(Millar et al, 2002; Wong et al, 2002). The tumorigenic effect may
be due to an increase in MF, decreased apoptosis or a combination
of both. However, absence of Mbd4 in an MSH2-null background
does not increase tumorigenicity above that seen owing to the
MMR-deficiency (Sansom et al, 2004).
In humans, a naturally occurring frameshift mutation of a
polynucleotide tract in MBD4 has been found in microsatellite
unstable (MSI) colon and other cancers (Bader et al, 1999; Riccio
et al, 1999; Menoyo et al, 2001; Yamada et al, 2002) that leads to a
premature stop in translation of the mRNA. The mutation occurs
in 20 –43% of cases (mixed tissue samples), whereas micro-
dissected samples (enriched for tumour cells) of 89% sporadic MSI
colon tumours had truncated MBD4 mutations in at least one focus
tested (Bader et al, 2000). Crucial in this study in human cells, for
comparison with prior studies in mice, the equivalent mutation of
Mbd4 is not present in MSI mouse models as the murine gene does
not contain a coding polyA microsatellite. The Mbd4-null
phenotype modeled in mice is an experimental condition only,
as in humans mutation or loss of MBD4 only occurs in the
presence of the frame-shifted allele. Although mutation in MBD4 is
thought to occur in MSI tumours as a consequence of the
microsatellite instability caused by mismatch repair (MMR)
protein inactivation, we have postulated that MBD4 mutation
may still affect tumour progression in humans. Bi-allelic inactiva-
tion of MBD4 (by frameshift mutation of both alleles, or of one
allele with chromosomal loss of the second) has been seen in a
small number of cases or samples (Bellacosa et al, 1999; Bader
et al, 2000). However, by far the most common condition appears
to be frameshift of one allele in the presence of a remaining normal
allele, and there has been no documented evidence of the null
genotype as studied in the mouse models. A recombinant N-
terminal portion of MBD4 containing amino acids (aa) 1 –165
including the MBD has been shown to be still able to bind to
methyl-CpG oligos including also those with T G mismatches
(Hendrich et al, 1999). It is therefore possible that the naturally-
occurring MBD4 mutation exerts a dominant negative effect, where
the truncated protein is not only defective in glycosylase activity,
but also can inhibit normal MBD4 function via competitive
binding of mismatch sites. In this study, we describe how
truncated MBD4 can inhibit normal glycosylase activity in a cell-
free system, and increase mutation frequency across a wide
spectrum of mutation changes in living colon cancer cells even on
a background of pre-existing MSI.
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MATERIALS AND METHODS
Recombinant proteins, in vitro transcription/translation
and Western immunoblots
For MBD4tru, random primed cDNA was made from HCT116 cells
and PCR amplified with forward primer 4NcoMet and MBD4.12A-
Bam. PCR product was double digested with NcoI and BamHI and
cloned into NcoIþBamHI digested bacterial expression vector
pET6H. Recombinant proteins were expressed in Escherichia coli
BLR (lDE3)/pLysS and purified over nickel-agarose columns
(Qiagen, West Sussex, UK) followed by Fractogel EMD SO3
2
650(M) columns (Merck) as described (Free et al, 2001). MBD4
proteins were also made by in vitro transcription/translation using
linearised MBD4 cDNA-containing pET6H plasmids in TNT
T7-coupled reticulocyte lysate (Promega, Hampshire, UK) in the
presence of [35S] Methionine.
Nuclear extracts from cell lines were made using the Proteo
Extract subcellular proteome extraction kit (Calbiochem, Nottin-
ghamshire, UK) according to the manufacturer’s instructions.
For Western immunoblotting, proteins were subjected to SDS–
PAGE on 10% BisTris NuPage gels (Invitrogen, Paisley, UK) in
MOPS buffer, blotted onto Hybond P membrane (Amersham,
Buckinghamshire, UK) and probed with antibodies using standard
protocols. Antibodies used were monoclonal anti-His tag (Novagen,
Nottinghamshire, UK), polyclonal anti-MBD4 (H-300, raised
against amino acids 281–580 and capable of binding to truncated
MBD4 with normal sequence up to residue 313, Santa Cruz) and
monoclonal anti-lamin B (Calbiochem).
Glycosylase assays
Assays were performed essentially as described before (Hendrich
et al, 1999), with modification of the piperidine cleavage assay
involving the inclusion not only of the active wt recombinant
glycosylase (MBD4 or UDG) but also a range of 0– 100 ng MBD4tru
as competitor in a constant volume. Briefly, 10 ng recombinant
wtMBD4 or 0.2 U uracil DNA glycosylase (New England Biolabs,
Hertfordshire, UK) protein was incubated with annealed oligo-
nucleotides (the reverse strand of each pair having been end-
labelled with [33P] ATP) with or without recombinant MBD4tru in a
constant total volume of 40 ml. Primer combinations (Hendrich
and Bird, 1998; Hendrich et al, 1999) used were BH:BHrev,
BH:BHrevU, MM2:MM3revU.
DNA for transfection
A portion of 2 mg of lLIZ (Big Blue shuttle vector, Stratagene,
Cambridgeshire, UK) DNA was methylated at 371C for 30 min in
vitro using excess SssI methylase according to the manufacturer’s
protocol (New England Biolabs), and then concatenated for 1 h at
room temperature using DNA ligase (New England Biolabs) before
transfection. MBD4tru cDNA was made by cloning the PCR product
from HCT116 cDNA (primers MBD4.1a and MBD4.14) into
pGEMT (Promega) and subsequently it was transferred into
pcDNA3 (Invitrogen). cDNA insert was sequenced by cycle
sequencing to confirm identity and presence of mutant A9
polynucleotide stretch as well as lack of any other introduced
mutations.
Cell lines and culture, including transfection
All cell lines except HCA7 were grown in RPMI1640þ 5% foetal
calf serum with selective agents used as described. HCA7 was
grown in DMEMþ 10% foetal calf serum. DLD1 cells were
cotransfected with 2 mg of lLIZ (prepared as above) and 500 ng
pcDNA3.1 Hygro (Invitrogen) using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s protocol for 24 wells. After
transfection, cells were seeded into 10 cm dishes and colonies were
selected using 300 mg ml1 hygromycin B (Invitrogen). Colonies
were screened for intact lLIZ by PCR amplification using primer
pairs spanning lacI and at the end of each arm of lLIZ. Successful
packaging of positive clones was checked using protocols
described below. Cell lines with lLIZ (T54c4, T54c10) were
transfected with PvuI-linearised MBD4tru.pcDNA3 expression
plasmid or PvuI-linearised empty vector, using Lipofectamine
2000 as described above, and colonies were selected using
600mg ml1 Geneticin (Invitrogen).
Methylation check of transfected kLIZ
A portion of 1 mg genomic DNA of cell lines was set up for
overnight digestion with no enzyme, HpaII or MspI. Samples were
then PCR amplified using primer pairs for B450 bp fragments of
either lacI (2A and 13A, spanning two HpaII/MspI sites) or the
CpG island of MBD1 (59 and 60, spanning three HpaII/MspI sites).
Where the CpG sites were methylated, HpaII did not cut and PCR
amplification could occur, whereas MspI cuts independent of
methylation. Controls for efficacy of digestion of DNA by HpaII of
unmethylated DNA were provided by the MBD1 samples (MBD1
being a constitutively expressed gene with unmethylated CpG
island).
Big Blue plaque assays and sequencing
Cell pellets were frozen at 701C and then used for DNA extraction
by the phenol–chloroform protocol as described in the Big Blue
Instruction Manual (Stratagene). The l shuttle vector containing
the lacI target gene was recovered from genomic DNAs as
described in the Big Blue Instruction Manual and packaged with
l packaging extract (Transpack, Stratagene). After initial dilution
plating of packaging reactions, a density of 10 000 PFU per plate
was targeted on 24.5 24.5 cm assay dishes, but each plating
session was accompanied by a 1/40th dilution plating and all
plaques counted for accurate assessment of the number of plaques
screened. Blue mutant plaques were identified against a red
background on a lightbox, and re-plated to verify as true mutants.
Mutant frequency was calculated by dividing the number of blue
plaques by the total number plated. Assays were performed for
DNAs packaged from at least four independent pellets of cells per
cell line, and usually between 250 000 and 400 000 PFU screened
per packaged DNA. At least 30 well-separated mutant plaques per
cell line were picked from plates for sequencing, starting from one
corner of the plate and working inwards to the centre with each
blue plaque encountered taken, so as to avoid any colour/mutation
bias. Cored plaques were placed in SM buffer, from which an
aliquot of buffer/phage suspension was taken and used as template
in PCR amplification of the entire lacI gene (primers 1A and 8 as in
the Stratagene manual). PCR products were then sequenced using
[33P]dATP and Thermosequenase cycle sequencing kits (Amersham)
from primers recommended in the Big Blue Instruction Manual
(Stratagene), the products run on 6% acrylamide : urea gels and
then exposed to autoradiographic film. To aid in visual screening
for mutant bases, samples were run in batches of 10, with all G’s
together, all A’s together and so on.
For analysis of mutation spectra, enough plaques were
sequenced to identify about 50 independent mutations (defined
as unique base changes at unique nucleotides, that is, disregarding
multiple incidences in different plaques) for each cell line.
Statistical analyses
Comparison of mutation frequencies was carried out by two-tailed
unpaired t-test. Statistical comparisons of mutation spectra were
carried out using the Monte Carlo approximation to Fisher’s exact
test of Adams and Skopek (1987), with 1700 iterations in a
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programme available on the web (Cariello et al, 1994) and the
significance level set at 0.05. The test conducts pairwise
comparisons using the 11 mutational classes shown in Figure 4B
and Supplementary Table 2), including the subset of G:C to A:T
mutations that occurred at CpG sites.
RESULTS
Preparation of recombinant proteins
We prepared recombinant His-tagged wild-type/full-length (FL-
MBD4) and truncated (MBD4tru) human MBD4 proteins for use in
glycosylase assays. MBD4tru comprises wild-type protein sequence
from aa 1 –313 with three further novel residues 314–316, and
includes the MBD (aa 80– 146) with 167 aa of intervening sequence
(see Figure 1A). For MBD4tru, we amplified PCR exons 1, 2, and
part of 3 of the gene from cDNA of HCT116 cells that are
heterozygous (A10/A9) and express both alleles (Bader et al, 1999).
Following transformation, bacterial colonies were screened by
PCR and cycle sequencing for the presence of A9 vs A10 allele, after
which the entire cDNA and flanking plasmid regions of a candidate
colony were sequenced to rule out mutations that may have arisen
during the cloning procedure. Recombinant proteins were then
expressed and purified. To confirm the apparent molecular
weights of the two purified recombinant proteins as seen on a
Western immunoblot probed with anti-His tag antibody
(Figure 1B), we used linearised plasmids to express protein from
plasmid T7 promoters in rabbit reticulocyte lysates and then
carried out SDS–PAGE (data not shown). Plasmids used contained
MBD4 cDNAs cloned in both the prokaryotic expression vector
and the eukaryotic expression vector transfected in experiments
described later. In each case, full-length MBD4 ran at an apparent
molecular weight of about 66 kDa and truncated MBD4 at about
43 kDa. The value for full-length protein is as expected from its
theoretical molecular weight, but is about 5 kDa larger for
truncated protein. Furthermore, Western analysis of nuclear
proteins of HCT116 (heterozygous wt/mut) and HCA7 (homo- or
hemi-zygous mutant) colorectal carcinoma cell lines with H-300
antibody detected both forms of MBD4 (Figure 1C). Only full-
length MBD4 was seen in T54c4 (DLD1 cells with endogenous
wtMBD4 and transfected only with lLIZ Big Blue shuttle vector)
and T72con1 (T54c4 transfected with empty pcDNA vector).
Truncated MBD4 was expressed in MBD4-mutant tumour cells
albeit at an apparently lower level. Barring any unknown post-
translational modifications that might reduce the affinity of H-300-
binding to MBD4tru, we predict that the lower level of MBD4tru is
due to nonsense-mediated decay of mRNA, typical of such
mutations (El-Bchiri et al, 2005). Figure 1D shows the Western
blot hybridisation for loading control nuclear protein lamin B.
Dominant negative inhibition in glycosylase assays
Cell-free assays with the purified recombinant proteins showed
that MBD4tru could inhibit T G glycosylase activity of full-length
MBD4 (Figure 2A). In this and the following assays, the amount
of cut oligo product generated by the activity of the wild-type
glycosylase was seen to decrease in the presence of increasing
amounts of MBD4tru, with an increase in the uncut oligo substrate
above. As MBD4 has been shown to be an efficient U G
glycosylase, we tested the ability of MBD4tru to inhibit this
function, and found that inhibition can also be seen (Figure 2B).
Our assays also showed that MBD4tru could competitively inhibit
U G glycosylase activity of another DNA repair enzyme that
MBD glyc.
580N
N 316
313
1
−64
−51
−39
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B C
D
Figure 1 Expression of full-length (FL) and truncated (tru) MBD4. (A)
Diagram of MBD4 proteins; the MBD4tru sequence is the same as FL up to
aa 313 after which there are three novel residues (KDH) owing to the
frameshift. (B) Purified recombinant proteins 1: tru, 2: FL, detected by
Western blot hybridisation with anti-His tag antibody. (C) MBD4 in nuclear
fractions of colorectal carcinoma cell lines 1: HCA7 2: HCT116 3: T54c4 4:
T72con1, detected by Western blot hybridisation with antibody H-300.
Arrows indicate endogenous FL (upper) and tru (lower) MBD4. (D)
Loading control Western blot using anti-lamin B.
−
− −
−
− −
−
−
+ + + + +
−
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Product
Product
Product
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Substrate
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C
Figure 2 Dominant negative inhibition of glycosylase activities in cell-free
glycosylase assays. (A) Oligo substrate BH:BHrev containing T.G mismatch,
and FL-MBD4 competed with MBD4tru. (B) Oligo substrate MM2:MM3revU
containing U.G mismatch, and FL-MBD4 competed with MBD4tru. (C)
Oligo substrate BH:BHrevU containing U.G mismatch, and UDG competed
with MBD4tru. In each case, ‘þ ’ indicates presence and ‘’ absence of
protein, and the wedge indicates relative concentration of MBD4tru in
roughly two-fold increments from 1 to 10 (A) or from 1 to 20 (B, C).
Vertical lines indicate where lanes have been juxtaposed owing to removal
of an intervening, non-two-fold incremental lane.
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recognises U G mismatches, Uracil DNA glycosylase (UDG)
(Figure 2C).
Big Blue cell lines
The Big Blue lLIZ reporter shuttle vector containing part of the
lacI-lacZ operon (Stratagene) was transfected into DLD1 cells that
are wild-type for MBD4. Although cellular methylation of
transfected LIZ was expected to occur as such foreign, silent
DNA usually undergoes this modification (as was the case Big Blue
mice; You et al, 1998), we wished to guarantee methylation of lLIZ
CpG sites at the outset and so pretreated lLIZ with SssI methylase
before transfection. Because lLIZ does not have a selectable
marker, it was cotransfected with pcDNA3 Hygro3.1 and clones
were selected with hygromycin B. Clones were screened by PCR for
presence of lLIZ and tested for packaging ability, before being
used for MF assays and further transfected with MBD4tru cDNA.
Two clones, T54c10 and T54c4 were generated, and they that
carried intact, concatenated lLIZ and packaged efficiently.
Methylation of the integrated lLIZ was confirmed by PCR
amplification of DNA digested with HpaII or MspII, spanning a
region of lacI containing two HpaII/MspI sites (Figure 3). Efficacy
of HpaII digestion was confirmed by PCR amplification of part of
the CpG island of an expressed, unmethylated gene (MBD1) from
the same digested DNA samples (Figure 3). The endogenous MBD4
genes of both T54c4 and T54c10 were also PCR amplified and
sequenced to confirm their polyA tract wild-type status. These two
clones were then transfected with MBD4tru cDNA expression
plasmid or empty vector alone, and geneticin-resistant clones were
isolated. MBD4tru cDNA-containing clones were confirmed by
PCR, and expression of the exogenous gene was verified by
Western blot hybridisation (Supplementary Figure 1).
MBD4tru increases mutation frequency
We next determined the mutation frequency (MF) of a human MSI
colon cancer cell line, DLD1, with/without MBD4truwe found that
the total MF increased in all clones transfected with MBD4tru. The
background spontaneous Big Blue mutation frequencies of the two
parental clones of DLD1 were 79 105 (T54c4) and 178 105
(T54c10) (Table 1). Expression of exogenous MBD4tru increased
the MF of T54c4 to 292–310 105 (two clones tested), and for
T54c10 to 306–440 105 (three clones tested) (all P-values
o0.05) (Table 1 and Supplementary Table 1). This is an increase in
total MF of about 2 –4 fold above that for parental cells and
indicates increased genomic instability beyond that due to pre-
existing MSI. Furthermore, sequencing of mutant plaques revealed
that a significant proportion of blues for each clone tested carried
one of several identical nucleotide changes (a ‘jackpot’ (Heddle
1999) mutation, that is, the same base change at the same base-pair
location and defined in our experiments as accounting for 46%,
or seen in two or more of 30 sequenced plaque samples) as shown
in Table 2 and Figure 4A. These identical changes represent more
likely a provenance as offspring from the same parental cell that
had suffered a mutation early in the expansion of the clone after
transfection, rather than independent de novo mutations.
Normally in Big Blue experiments using drug-treated animals,
jackpot mutations are disregarded as confounding data resulting
from clonal expansion in a subset of cells created during tissue
development in vivo. However, given the structure of the in vitro
experiments described here involving sequential transfection of
individual cells with the applied stress factor (expressed mutant
gene, rather than drug applied to a whole mixed cell population),
the jackpots enable us to evaluate further the increased MF.
Allowing for chance occurrence of a mutation at any given time
followed by clonal expansion, the data can be interpreted as
follows: the greater is the jackpot effect (number of jackpots and/or
proportion of the MF), the greater is the underlying genomic
instability. Furthermore, the relative proportion of MF accounted
for by any one jackpot gives an indication of how early during
clonal expansion after transfection that jackpot occurred. The
extreme example of this is the T72c2 cell line where, of the 30
plaques sequenced, 28 carried the same mutation, suggesting an
event that occurred very early after transfection and selection.
As expected, three of the four control clones transfected with
empty expression vector (i.e. no applied stress factor) displayed a
range of MF, but roughly equivalent to the parental clone T54c4.
One control, T72con1, did have an MF almost double that of its
parent and this was found to be due to jackpots. Presumably in this
particular instance, these jackpots occurred as a result of the
innate MSI of the T54c4 parent, but by chance earlier during clonal
expansion than for its parental or sibling control clones. The
results therefore confirm that the parental DLD1 MSI cell line has
T54c10 T57c12 T57c32 T57c45
lac I
MBD1
--- H M --- H M --- H M --- H M
Figure 3 Methylation of transfected lLIZ shuttle vector. Genomic DNA
of cell lines was digested with HpaII (H), MspI (M) or treated with no
enzyme (), and then PCR amplified using primer pairs to amplify a CpG-
rich part of (A) transfected lLIZ or (B) endogenous MBD1 gene. Cell lines
shown are T54c10 (clone of DLD1 þ lLIZ) and T57c12, c32, 45 (all
clones of T54c10 þMBD4tru).
Table 1 Big Blue mutation frequencies in cell lines, summary
Cell line MBD4tru
mean MF
105 s.d. P
Relative MF
increasea
T54c10  178 47
T57c12 + 327 28 2.27 104 1.8
T57c32 + 440 19 8.64 106 2.5
T57c45 + 306 28 3.38 103 1.7
T54c4  79 6
T72c2 + 310 37 8.27 108 3.9
T73c13 + 242 131 1.34 103 3.1
T72con1  157 30 4.83 104 2.0
T72con2  81 41 0.64 1.0
T72con3  83 9 0.45 1.0
T72con4  60 5 7.23 104 0.8
a‘relative increase’ compared with –MBD4tru parental cell line T54c10 or T54c4
Table 2 Jackpot mutations
Cell
line MBD4tru
No.
plaques
sequenced
No.
jackpots
Total % of
MF owing to
jackpots Base changes
T54c10 76 2 25 A to G, T to G
T57c12 + 97 1 20 T to A
T57c32 + 124 2 61 A to G, T to C
T57c45 + 30 4 40 T to C, A to G, G
to A (in CpG), C
to T
T54c4 30 2 17 C to T, T to C
T72c2 + 30 1 93 G to A
T73c13 + 30 3 60 C to T, G to A, A
to T
T72con1 + 30 2 57 T to C
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an MF that is itself higher than that for normal, genomically stable
somatic cells. It also highlights that the sensitivity of this assay
system to detect small changes in mutation frequency is limited. In
addition, our data demonstrate that genomic instability, as evinced
by overall MF and the proportion of MF owing to an increased
number of jackpots, increases further in the presence of MBD4tru.
MBD4tru affects a wide mutation spectrum
The mutation spectra of three cell lines (parental T54c10 and two
þMBD4tru clones T57c12 and T57c32) were determined by
sequencing about 50 independent mutations. These spectra
showed that the mutations occurring in the presence of MBD4tru
spanned the spectrum of possible changes with no bias towards
G:C to A:T transitions at CpG sites and no significant difference
from the parental cell line containing only wild-type MBD4
(T54c10 vs T57c12 P¼ 0.48, T54c10 vs T57c32 P¼ 0.52) (Figure 4B
and Supplementary Table 2). In addition, the base changes found
in the jackpots included examples of several types of base change
(Table 2). This is in contrast to the shift of mutation spectra in the
absence of Mbd4 in the mouse model, where the predominant
change seen is an increase in C to T transitions at methyl-CpG
sites.
DISCUSSION
The role of MBD4 was initially thought to be limited to the
detection and repair of T G mismatches that occur at methyl-CpG
dinucleotides as a result of deamination of the methyl-C. This was
demonstrated by the behaviour of recombinant protein in cell-free
gel-shift and glycosylase systems. Some other base-pair mis-
matches affecting CpG dinucleotides were also shown to be lower
affinity substrates for MBD4 activity (Petronzelli et al, 2000a, b)
and as time has progressed more substrates have been documen-
ted, at least in vitro (Liu et al, 2002; Yoon et al, 2003). The role of
MBD4 as a methyl-CpG-focused DNA mismatch glycosylase was
subsequently supported by increases in mutation frequency at CpG
sites in mouse models lacking Mbd4 (Millar et al, 2002; Wong et al,
2002). However, we and others have found an association of
truncating mutations of MBD4 in human MSI cancers, especially
colon, and in most cases these mutations occur in the presence of a
remaining intact MBD4 allele (Bader et al, 1999, 2000; Riccio et al,
1999), that is, the null genotype is not seen naturally. As the MBD
of MBD4 was reported to be able to bind methylated oligos with a
T G mismatch, we have hypothesised that a dominant negative
activity could be present in cells heterozygous for an MBD4tru
mutation that has occurred as a result of prior MMR gene
abnormality. In the absence of any known dimerisation of MBD4
molecules for activity, we envision the inhibition to occur via steric
recognition and competition for binding sites. In this study, we
have shown that MBD4tru can indeed inhibit glycosylase activity
of wtMBD4 and at least one other glycosylase (UDG) in cell-free
assays.
We went on to determine the mutation frequencies of living cells
using the lLIZ shuttle vector as an indicator. This is the first time
that the Big Blue system has been reported using human cells so
there are no prior reports of MF of the lacI gene in human cells or
tissues for comparison. However, the values of the parental clones
T54c10 and T54c4 are between 16 and 90 the spontaneous MF
of lLIZ in somatic tissues of untreated Big Blue mice (lacI reporter
system) and a similar lacZ transgenic mouse reporter system,
ranging from 2 to 5 105 in several reports (Morrison and
Ashby, 1994). The high MF of these clones of DLD1 is due to the
defect in the MSH6 MMR gene of this cell line, and similarly, high
MF of DLD1 or other MSI colon cancer cells compared with
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normal diploid fibroblasts has been reported elsewhere using
the HPRT or ouabainR endogenously expressed gene systems
(Bhattacharyya et al, 1994, 1995). We found that expression of
MBD4tru roughly doubles mutation frequency in cells even on the
background of MMR defect, on agreement with the dominant
negative hypothesis. The increase in genomic instability was
indicated not only by an increase in overall MF, but also the
relative effect of jackpot mutations. The latter observation was also
a novel interpretation of Big Blue data, useful in this instance of
cell culture rather than the usual animal experiments.
The first report of substrates of MBD4 showed preference for
T G products of methyl-C deamination within methyl-CpG sites
(Hendrich et al, 1999). Later reports demonstrated a larger set of in
vitro CpG mismatches for MBD4 recognition, such as U G
(Petronzelli et al, 2000a, b), 5-fluorouracil (5-FU) G (Petronzelli
et al, 2000b), ethenecytosine (eC) G (Petronzelli et al, 2000a),
5-formyluracil (5-FoU) G (Liu et al, 2002), T O6-methyl-guanine
(O6-meG) (Cortellino et al, 2003) and thymine glycol (Tg) G
(Yoon et al, 2003). Total absence of MBD4 in mice caused an
increase in MF especially at CpG sites (Millar et al, 2002; Wong
et al, 2002). This was as predicted from the originally reported
range of substrates and by the fact that the other main T G
mismatch enzyme, Thymine DNA glycosylase (TDG), does not
have an MBD and so does not focus on methyl-CpG sites. Repair of
T G and U G mismatches at non-methylated CpG sites, an Mbd4
function lost in Mbd4-null cells, would be covered by redundant
glycosylases TDG and UDG. We had predicted that dominant
negative action of MBD4tru would likewise increase C to T
transitions, especially at methyl-CpG sites in human cells, owing
to inhibition of wtMBD4 with some gain-of-function inhibition of
TDG and UDG. Our observation that the mutation spectrum in the
presence of MBD4tru does not specifically show an increase of C to
T transitions at methyl-CpG sites, but instead increases mutation
frequency across the entire spectrum, implies that MBD4tru not
only inhibits wtMBD4 activity at methyl-CpG sites, but also
activities of the other glycosylases at least, and perhaps also other
DNA repair pathways. This conclusion is consistent with the data
implicating MBD4 in a wider role of DNA damage substrate
recognition and repair leading to apoptosis in Mbd4-null mice
(Sansom et al, 2003; Screaton et al, 2003) treated with for example
the methylating agent temozolamide and the crosslinking chemical
cisplatin. The important difference between the mouse studies and
this is that the effects presented here occurred owing to expression
of a naturally occurring truncation mutant of MBD4 found in
authentic human tumours. The agreed sequence of events in
human tumours involves a mutational event that leads to an MMR
gene abnormality thus causing the MSI phenotype that then by
chance hits an MBD4 allele. The dominant negative activities of
MBD4tru in our experiments suggest that wtMBD4 is involved
directly in more than just methyl-CpG repair or that MBD4tru is
able to interfere nonspecifically in repair systems, or both. The
former is consistent with the data from Mbd4 knockout
experiments. The increase in MF seen here following relatively
short-term culture with a high level of expression of truncated
MBD4 is demonstration in principle of the dominant negative
effect of this mutant protein. In the physiological situation with
expression of endogenous truncated MBD4 at a relatively lower
level because of NMD, the increase in MF is also expected to be
less. In this way, NMD has an important role in protecting cells
from damaging activities of frameshifting mutations. However, in
view of the stochastic nature of mutations arising as a result of
perturbed DNA repair, over the extended period of time of 5– 20
years that it takes to get malignant colon tumours, even in patients
with MSI owing to HNPCC, it is feasible for even the low level of
MBD4tru to compound the genomic instability owing to MMR
defects. Such dominant negative interference with a tumour cell’s
biology may also have relevance to therapeutic intervention. We
are in the process of using the same cell lines to test for changes in
sensitivity to DNA-damaging agents with respect to signaling to
apoptosis, and it is possible that cells carrying MBD4tru mutations
will also be more tolerant of the types of damage tested in Mbd4-
null systems. It will also be important to study the effects of
MBD4tru at more physiological levels, for example, by creating a
mouse knock-in model whereby a truncated Mbd4 allele is
expressed under the control of the endogenous promoter.
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